First-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer

被引：0

作者：

Sharma, Manish

Strickler, John H.

Sommerhalder, David

Kuboki, Yasutoshi

Perets, Ruth

Cohen, Jonathan

Raimbourg, Judith

Nakajima, Takako Eguchi

Yamamoto, Noboru

Cruz-Correa, Marcia

O'Neil, Bert

Ghiringhelli, Francois

Raghav, Kanwal Pratap Singh

Li, Rui

Thiele, Gladys Morrison

Aristide, Martha Raluca Neagu

Freise, Kevin Jay

de Almeida, Carla Biesdorf

Vasilopoulos, Athanasios

Powderly, John D., II

机构：

[1] START Midwest, Grand Rapids, MI USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] NEXT Oncol, San Antonio, TX USA

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Rambam Med Ctr, Haifa, Israel

[6] Technion Israel Inst Technol, Haifa, Israel

[7] Hebrew Univ Jerusalem, Sharett Inst Oncol, Wohl Inst Translat Med, Hadassah Med Ctr,Hadassh Hebrew Univ Med Ctr, Jerusalem, Israel

[8] Ctr Rene Gauducheau, Insit Cancerol Ouest, St Herblain, France

[9] Kyoto Univ, Grad Sch Med, Kyoto, Japan

[10] Natl Canc Ctr, Tokyo, Japan

[11] Univ Puerto Rico, Med Sci Campus, San Juan, PR USA

[12] Pan Amer Ctr Oncol Trials, San Juan, PR USA

[13] Community Hlth Canc Ctr North, Indianapolis, IN USA

[14] Ctr Georges Francois Leclerc, Dijon, France

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[16] AbbVie Inc, N Chicago, IL USA

[17] Carolina Biooncol Inst, Huntersville, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3515

引用

页数：1

共 50 条

[21] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana, Sreenivasa R.
Choudhury, Noura J.
Dowlati, Afshin
Chiang, Anne C.
Garmezy, Benjamin
Kim, Joo-Hang
Byers, Lauren Averett
Ahn, Myung-Ju
Kim, Tae Min
Kim, Young-Chul
Han, Ji-Youn
Bar, Jair
Zha, Jiuhong
Henner, William
Robinson, Randy
Kohlhapp, Fred
Hingorani, Pooja
Papadopoulos, Kyriakos P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22] In vitro and in vivo activity of a novel c-Met-targeting antibody-drug conjugate using a DNA-alkylating, indolinobenzodiazepine payload
Lai, Katharine C.
Muvaffak, Asli
Li, Min
Themeles, Marian
Sikka, Surina
Donahue, Kerry
Hicks, Stuart W.
Romanelli, Angela
Chittenden, Thomas
CANCER RESEARCH, 2017, 77
[23] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018)
Strickler, J. H.
Weekes, C. D.
Nemunaitis, J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 261 - 261
[24] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
De Miguel, M.
Yamamoto, N.
Raimbourg, J.
Cho, B. C.
Gottfried, M.
Stemmer, S. M.
Goldman, J. W.
Blaney, M. E.
Jennaro, T.
Vasilopoulos, A.
Li, R. R.
Freise, K. J.
Aristide, M. R. Neagu
Morrison-Thiele, G.
Hunter, Z. N.
Burns, M.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
[25] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Zhao, H.
Ma, Y.
Meng, X.
Wu, L.
Fan, Y.
Zheng, Y.
Liu, Z.
Ji, Y.
Lv, D.
Luo, S.
Sommerhalder, D.
Fu, S.
Huang, Y.
Yang, Y.
Fang, W.
Zhao, Y.
Wang, Y.
Chin, S.
Xue, T.
Zhang, L.
ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
[26] EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors
Aggarwal, Charu
Azzoli, Christopher G.
Spira, Alexander I.
Solomon, Benjamin J.
Le, Xiuning
Rolfo, Christian
Planchard, David
Felip, Enriqueta
Wu, Yi-Long
Ahn, Myung-Ju
Seiwert, Tanguy Y.
Goto, Koichi
Azaro, Analia
Lissa, Delphine
Hamid, Oday
McGrath, Lara
Maudsley, Rhiannon
Arnaldez, Fernanda I.
Grenga, Italia
Massarelli, Erminia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
Wang, Yakun
Gong, Jifang
Lin, Rongbo
Zhao, Shen
Wang, Jufeng
Wang, Qianli
Zhang, Yanqiao
Su, Dan
Zhang, Jingdong
Dong, Qian
Lin, Ling
Tian, Wen
Chen, Ying
Yang, Yang
Zhang, Xueyuan
Wan, Xuechao
Gao, Jinfeng
An, Na
Jansen, Valerie Malyvanh
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Garrido-Laguna, Ignacio
Krop, Ian
Burris, Howard A., III
Hamilton, Erika
Braiteh, Fadi
Weise, Amy M.
Abu-Khalaf, Maysa
Werner, Theresa L.
Pirie-Shepherd, Steven
Zopf, Christopher J.
Lakshminarayanan, Mani
Holland, Jaymes S.
Baffa, Raffaele
Hong, David S.
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) : 1798 - 1808
[29] First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors
Meric-Bernstam, Funda
Oh, Do-Youn
Naito, Yoichi
Shimizu, Toshio
Chung, Vincent
Park, Haeseong
Gaillard, Stephanie
Wang, Fujun
Cooper, Zachary A.
Kinneer, Krista
Rebelatto, Marlon
Kirby, Lyndon
Luheshi, Nadia
Miller, Neil
Varga, Andreea
Mileshkin, Linda R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors
Coward, Jim
Kichenadasse, Ganessan
Park, John J.
Parakh, Sagun
Richardson, Gary Edward
Voskoboynik, Mark
Powderly, John D., II
Song, Zhengbo
Liu, Shutong
Huang, Yaling
Liu, Shu-Hui
Meng, Xun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →